title: Antirejection treatment in kidney transplantation--is there a proved rationale for the general use of monoclonal antibodies?
authors.affiliation: Department of Surgery, University of Tübingen, FRG.
authors.forename: H J
authors.initials: HJ
authors.lastname: Reis
authors.forename: U T
authors.initials: UT
authors.lastname: Hopt
authors.forename: B
authors.initials: B
authors.lastname: Greger
authors.forename: W D
authors.initials: WD
authors.lastname: Schareck
authors.forename: H
authors.initials: H
authors.lastname: Bockhorn
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation; D009894:Opportunistic Infections / Q000150:complications; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum